Abul-Milh, M, Paradis, SE, Dubreuil, JD and Jacques, M (1999). Binding of Actinobacillus pleuropneumoniae lipopolysaccharides to glycosphingolipids evaluated by thin-layer chromatography. Infection and Immunity 67: 4983–4987.
Alcon, VL, Foldvari, M, Snider, M, Willson, P, Gomis, S, Hecker, R, Babiuk, LA and Baca-Estrada, ME (2003). Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). Vaccine 21: 1811–1814.
Alcon, V, Baca-Estrada, M, Vega-Lopez, M, Willson, P, Babiuk, LA, Kumar, P, Hecker, R and Foldvari, M (2005). Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. The AAPS Journal 7: E566–E571.
Andresen, LO, Jacobsen, MJ and Nielsen, JP (1997). Experimental vaccination of pigs with an Actinobacillus pleuropneumoniae serotype 5b capsular polysaccharide-tetanus toxoid conjugate. Acta Veterinaria Scandinavica 38: 283–293.
Appleyard, GD, Furesz, SE and Wilkie, BN (2002). Blood lymphocyte subsets in pigs vaccinated and challenged with Actinobacillus pleuropneumoniae. Veterinary Immunology and Immunopathology 86: 221–228.
Autret, N, Dubail, I, Trieu-Cuot, P, Berche, P and Charbit, A (2001). Identification of new genes involved in the virulence of Listeria monocytogenes by signature-tagged transposon mutagenesis. Infection and Immunity 69: 2054–2065.
Backstrom, L (1999). Present uses of and experiences with swine vaccines. Advances in Veterinary Medicine 41: 419–428.
Bagdasarian, MM, Nagai, M, Frey, J and Bagdasarian, M (1999). Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit. Vaccine 17: 441–447.
Baltes, N and Gerlach, GF (2004). Identification of genes transcribed by Actinobacillus pleuropneumoniae in necrotic porcine lung tissue by using selective capture of transcribed sequences. Infection and Immunity 72: 6711–6716.
Baltes, N, Tonpitak, W, Gerlach, GF, Hennig-Pauka, I, Hoffmann-Moujahid, A, Ganter, M and Rothkotter, HJ (2001). Actinobacillus pleuropneumoniae iron transport and urease activity: effects on bacterial virulence and host immune response. Infection and Immunity 69: 472–478.
Baltes, N, Hennig-Pauka, I, Jacobsen, I, Gruber, AD and Gerlach, GF (2003). Identification of dimethyl sulfoxide reductase in Actinobacillus pleuropneumoniae and its role in infection. Infection and Immunity 71: 6784–6792.
Baltes, N, Buettner, FF and Gerlach, GF (2007). Selective capture of transcribed sequences (SCOTS) of Actinobacillus pleuropneumoniae in the chronic stage of disease reveals an HlyX-regulated autotransporter protein. Veterinary Microbiology 123: 110–121.
Beaudet, R, Mcsween, G, Boulay, G, Rousseau, P, Bisaillon, JG, Descoteaux, JP and Ruppanner, R (1994). Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination. Veterinary Microbiology 39: 71–81.
Beddek, AJ, Sheehan, BJ, Bosse, JT, Rycroft, AN, Kroll, JS and Langford, PR (2004). Two TonB systems in Actinobacillus pleuropneumoniae: their roles in iron acquisition and virulence. Infection and Immunity 72: 701–708.
Bei, W, He, Q, Yan, L, Fang, L, Tan, Y, Xiao, S, Zhou, R, Jin, M, Guo, A, Lv, J, Huang, H and Chen, H (2005). Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker. FEMS Microbiology Letters 243: 21–27.
Bei, W, He, Q, Zhou, R, Yan, L, Huang, H and Chen, H (2007). Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(−) mutant lacking a drug resistance marker in the pigs. Veterinary Microbiology 125: 120–127.
Belanger, M, Dubreuil, D, Harel, J, Girard, C and Jacques, M (1990). Role of lipopolysaccharides in adherence of Actinobacillus pleuropneumoniae to porcine tracheal rings. Infection and Immunity 58: 3523–3530.
Blackall, PJ, Klaasen, HL, Van Den Bosch, H, Kuhnert, P and Frey, J (2002). Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Veterinary Microbiology 84: 47–52.
Bosse, JT, Johnson, RP, Nemec, M and Rosendal, S (1992). Protective local and systemic antibody responses of swine exposed to an aerosol of Actinobacillus pleuropneumoniae serotype 1. Infection and Immunity 60: 479–484.
Bosse, JT, Janson, H, Sheehan, BJ, Beddek, AJ, Rycroft, AN, Kroll, JS and Langford, PR (2002). Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes and Infection/Institut Pasteur 4: 225–235.
Bouvet, JP, Decroix, N and Pamonsinlapatham, P (2002). Stimulation of local antibody production: parenteral or mucosal vaccination? Trends in Immunology 23: 209–213.
Byrd, W and Hooke, AM (1997). Immunization with temperature-sensitive mutants of Actinobacillus pleuropneumoniae induces protective hemolysin-neutralizing antibodies in mice. Current Microbiology 34: 149–154.
Byrd, W and Kadis, S (1992). Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants. Infection and Immunity 60: 3042–3051.
Challacombe, SJ (1987). Cellular factors in the induction of mucosal immunity by oral immunization. Advances in Experimental Medicine and Biology 216B: 887–899.
Chiers, K, Van Overbeke, I, De Laender, P, Ducatelle, R, Carel, S and Haesebrouck, F (1998). Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. The Veterinary Quarterly 20: 65–69.
Chung, JW, Ng-Thow-Hing, C, Budman, LI, Gibbs, BF, Nash, JH, Jacques, M and Coulton, JW (2007). Outer membrane proteome of Actinobacillus pleuropneumoniae: LC-MS/MS analyses validate in silico predictions. Proteomics 7: 1854–1865.
Cotter, SE, Yeo, HJ, Juehne, T and St Geme, JW III (2005). Architecture and adhesive activity of the Haemophilus influenzae Hsf adhesin. Journal of Bacteriology 187: 4656–4664.
Cox, E, Van Der Stede, Y, Verdonck, F, Snoeck, V, Van Den Broeck, W and Goddeeris, B (2002). Oral immunisation of pigs with fimbrial antigens of enterotoxigenic E. coli: an interesting model to study mucosal immune mechanisms. Veterinary Immunology and Immunopathology 87: 287–290.
Cruijsen, T, Van Leengoed, LA, Ham-Hoffies, M and Verheijden, JH (1995). Convalescent pigs are protected completely against infection with a homologous Actinobacillus pleuropneumoniae strain but incompletely against a heterologous-serotype strain. Infection and Immunity 63: 2341–2343.
Cruijsen, TL, Van Leengoed, LA, Dekker-Nooren, TC, Schoevers, EJ and Verheijden, JH (1992). Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolar macrophages and polymorphonuclear leukocytes isolated from pigs. Infection and Immunity 60: 4867–4871.
Cruz, WT, Nedialkov, YA, Thacker, BJ and Mulks, MH (1996). Molecular characterization of a common 48-kilodalton outer membrane protein of Actinobacillus pleuropneumoniae. Infection and Immunity 64: 83–90.
Deneer, HG and Potter, AA (1989). Identification of a maltose-inducible major outer membrane protein in Actinobacillus (Haemophilus) pleuropneumoniae. Microbial Pathogenesis 6: 425–432.
Deslandes, V, Nash, JH, Harel, J, Coulton, JW and Jacques, M (2007). Transcriptional profiling of Actinobacillus pleuropneumoniae under iron-restricted conditions. BMC Genomics 8: 72.
Dom, P, Haesebrouck, F, Ducatelle, R and Charlier, G (1994). In vivo association of Actinobacillus pleuropneumoniae serotype 2 with the respiratory epithelium of pigs. Infection and Immunity 62: 1262–1267.
Dubreuil, JD, Jacques, M, Mittal, KR and Gottschalk, M (2000). Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Animal Health Research Reviews/Conference of Research Workers in Animal Diseases 1: 73–93.
Felnerova, D, Kudela, P, Bizik, J, Haslberger, A, Hensel, A, Saalmuller, A and Lubitz, W (2004). T cell-specific immune response induced by bacterial ghosts. Medical Science Monitor 10: BR362–BR370.
Fenwick, B and Henry, S (1994). Porcine pleuropneumonia. Journal of the American Veterinary Medical Association 204: 1334–1340.
Frey, J (1995a). Exotoxins of Actinobacillus pleuropneumoniae. In: Donachie, W (ed.) Haemophilus, Actinobacillus, and Pasteurella. New York and London: Plenum.
Frey, J (1995b). Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends in Microbiology 3: 257–261.
Frey, J, Kuhnert, P, Villiger, L and Nicolet, J (1996). Cloning and characterization of an Actinobacillus pleuropneumoniae outer membrane protein belonging to the family of PAL lipoproteins. Research in Microbiology 147: 351–361.
Fuller, TE, Thacker, BJ and Mulks, MH (1996). A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine. Infection and Immunity 64: 4659–4664.
Fuller, TE, Shea, RJ, Thacker, BJ and Mulks, MH (1999). Identification of in vivo induced genes in Actinobacillus pleuropneumoniae. Microbial Pathogenesis 27: 311–327.
Fuller, TE, Kennedy, MJ and Lowery, DE (2000a). Identification of Pasteurella multocida virulence genes in a septicemic mouse model using signature-tagged mutagenesis. Microbial Pathogenesis 29: 25–38.
Fuller, TE, Martin, S, Teel, JF, Alaniz, GR, Kennedy, MJ and Lowery, DE (2000b). Identification of Actinobacillus pleuropneumoniae virulence genes using signature-tagged mutagenesis in a swine infection model. Microbial Pathogenesis 29: 39–51.
Fuller, TE, Thacker, BJ, Duran, CO and Mulks, MH (2000c). A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine. Vaccine 18: 2867–2877.
Furesz, SE, Mallard, BA, Bosse, JT, Rosendal, S, Wilkie, BN and Macinnes, JI (1997) Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs. Infection and Immunity 65: 358–365.
Furesz, SE, Wilkie, BN, Mallard, BA, Rosendal, S and Macinnes, JI (1998). Anti-haemolysin IgG1 to IgG2 ratios correlate with haemolysin neutralization titres and lung lesion scores in Actinobacillus pleuropneumoniae infected pigs. Vaccine 16: 1971–1975.
Garside, LH, Collins, M, Langford, PR and Rycroft, AN (2002). Actinobacillus pleuropneumoniae serotype 1 carrying the defined aroA mutation is fully avirulent in the pig. Research in Veterinary Science 72: 163–167.
Gerdts, V, Mutwiri, GK, Tikoo, SK and Babiuk, LA (2006). Mucosal delivery of vaccines in domestic animals. Veterinary Research 37: 487–510.
Gerlach, GF, Anderson, C, Potter, AA, Klashinsky, S and Willson, PJ (1992a). Cloning and expression of a transferrin-binding protein from Actinobacillus pleuropneumoniae. Infection and Immunity 60: 892–898.
Gerlach, GF, Klashinsky, S, Anderson, C, Potter, AA and Willson, PJ (1992b). Characterization of two genes encoding distinct transferrin-binding proteins in different Actinobacillus pleuropneumoniae isolates. Infection and Immunity 60: 3253–3261.
Gerlach, GF, Anderson, C, Klashinsky, S, Rossi-Campos, A, Potter, AA and Willson, PJ (1993). Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1. Infection and Immunity 61: 565–572.
Goethe, R, Gonzales, OF, Lindner, T and Gerlach, GF (2000). A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction. Vaccine 19: 966–975.
Gonzalez, GC, Caamano, DL and Schryvers, AB (1990). Identification and characterization of a porcine-specific transferrin receptor in Actinobacillus pleuropneumoniae. Molecular Microbiology 4: 1173–1179.
Goonetilleke, NP, Mcshane, H, Hannan, CM, Anderson, RJ, Brookes, RH and Hill, AV (2003). Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. Journal of Immunology 171: 1602–1609.
Graham, JE and Clark-Curtiss, JE (1999). Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proceedings of the National Academy of Sciences, USA 96: 11554–11559.
Green, J, Sharrocks, AD, Macinnes, JI and Guest, JR (1992). Purification of HlyX, a potential regulator of haemolysin synthesis, and properties of HlyX:FNR hybrids. Proceedings 248: 79–84.
Grifantini, R, Bartolini, E, Muzzi, A, Draghi, M, Frigimelica, E, Berger, J, Ratti, G, Petracca, R, Galli, G, Agnusdei, M, Giuliani, MM, Santini, L, Brunelli, B, Tettelin, H, Rappuoli, R, Randazzo, F and Grandi, G (2002). Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nature Biotechnology 20: 914–921.
Habrun, B, Bilic, V, Cvetnic, Z, Humski, A and Benic, M (2002). Porcine pleuropneumonia: the first evaluation of field efficacy of a subunit vaccine in Croatia. Veterinary Medicine – Czech 47: 213–218.
Haesebrouck, F, Van De Kerkhof, A, Dom, P, Chiers, K and Ducatelle, R (1996). Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs. Veterinary Microbiology 52: 277–284.
Haesebrouck, F, Chiers, K, Van Overbeke, I and Ducatelle, R (1997). Actinobacillus pleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis and protection. Veterinary Microbiology 58: 239–249.
Haesebrouck, F, Pasmans, F, Chiers, K, Maes, D, Ducatelle, R and Decostere, A (2004). Efficacy of vaccines against bacterial diseases in swine: what can we expect? Veterinary Microbiology 100: 255–268.
Haga, Y, Ogino, S, Ohashi, S, Ajito, T, Hashimoto, K and Sawada, T (1997). Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. Journal of Veterinary Medical Science 59: 115–120.
Hensel, A, Stockhofe-Zurwieden, N, Petzoldt, K and Lubitz, W (1995). Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infection and Immunity 63: 3048–3053.
Hensel, A, Van Leengoed, LA, Szostak, M, Windt, H, Weissenbock, H, Stockhofe-Zurwieden, N, Katinger, A, Stadler, M, Ganter, M, Bunka, S, Pabst, R and Lubitz, W (1996). Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. Journal of Biotechnology 44: 171–181.
Hensel, A, Huter, V, Katinger, A, Raza, P, Strnistschie, C, Roesler, U, Brand, E and Lubitz, W (2000). Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18: 2945–2955.
Higgins, R, Lariviere, S, Mittal, KR, Martineau, GP, Rousseau, P and Cameron, J (1985). Evaluation of a killed vaccine against porcine pleuropneumonia due to Haemophilus pleuropneumoniae. Canadian Veterinary Journal 26: 86–89.
Hodgetts, A, Bosse, JT, Kroll, JS and Langford, PR (2004). Analysis of differential protein expression in Actinobacillus pleuropneumoniae by Surface Enhanced Laser Desorption Ionisation – ProteinChip (SELDI) technology. Veterinary Microbiology 99: 215–225.
Huter, V, Hensel, A, Brand, E and Lubitz, W (2000). Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. Journal of Biotechnology 83: 161–172.
Ingham, A, Zhang, Y and Prideaux, C (2002). Attenuation of Actinobacillus pleuropneumoniae by inactivation of aroQ. Veterinary Microbiology 84: 263–273.
Inzana, TJ, Ma, J, Workman, T, Gogolewski, RP and Anderson, P (1988). Virulence properties and protective efficacy of the capsular polymer of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5. Infection and Immunity 56: 1880–1889.
Inzana, TJ, Todd, J, Ma, JN and Veit, H (1991). Characterization of a non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: role of the 110 kilodalton hemolysin in virulence and immunoprotection. Microbial Pathogenesis 10: 281–296.
Inzana, TJ, Todd, J and Veit, HP (1993). Safety, stability, and efficacy of noncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines. Infection and Immunity 61: 1682–1686.
Inzana, TJ, Glindemann, G, Fenwick, B, Longstreth, J and Ward, D (2004). Risk assessment of transmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae. Veterinary Microbiology 104: 63–71.
Jacobsen, MJ, Nielsen, JP and Nielsen, R (1996). Comparison of virulence of different Actinobacillus pleuropneumoniae serotypes and biotypes using an aerosol infection model. Veterinary Microbiology 49: 159–168.
Jacques, M (1996). Role of lipo-oligosaccharides and lipopolysaccharides in bacterial adherence. Trends in Microbiology 4: 408–409.
Jacques, M (2004). Surface polysaccharides and iron-uptake systems of Actinobacillus pleuropneumoniae. Canadian Journal of Veterinary Research=Revue Canadienne de Recherche Veterinaire 68: 81–85.
Jacques, M, Belanger, M, Roy, G and Foiry, B (1991). Adherence of Actinobacillus pleuropneumoniae to porcine tracheal epithelial cells and frozen lung sections. Veterinary Microbiology 27: 133–143.
Jalava, K, Eko, FO, Riedmann, E and Lubitz, W (2003). Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Review of Vaccines 2: 45–51.
Jansen, R (1994). The RTX toxins of Actinobacillus pleuropneumoniae. PhD Thesis, DLO-Central Veterinary Institute, Lelystad, The Netherlands.
Jolie, RA, Mulks, MH and Thacker, BJ (1995). Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Veterinary Microbiology 45: 383–391.
Katinger, A, Lubitz, W, Szostak, MP, Stadler, M, Klein, R, Indra, A, Huter, V and Hensel, A (1999). Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. Journal of Biotechnology 73: 251–260.
Kaul, D and Ogra, PL (1998). Mucosal responses to parenteral and mucosal vaccines. Developments in Biological Standardization 95: 141–146.
Kilian, M, Mestecky, J and Russell, MW (1988). Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiological Reviews 52: 296–303.
Kim, T and Lee, J (2006). Cloning and expression of genes encoding transferrin-binding protein A and B from Actinobacillus pleuropneumoniae serotype 5. Protein Expression and Purification 45: 235–240.
Kim, TJ, Kim, KH and Lee, JI (2007). Stimulation of mucosal and systemic antibody responses against recombinant transferrin-binding protein B of Actinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 69: 535–539.
Krieg, AM (2000). Immune effects and mechanisms of action of CpG motifs. Vaccine 19: 618–622.
Kunkel, EJ and Butcher, EC (2003). Plasma-cell homing. Nature Reviews 3: 822–829.
Lee, KY, Kim, DH, Kang, TJ, Kim, J, Chung, GH, Yoo, HS, Arntzen, CJ, Yang, MS and Jang, YS (2006). Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS Immunology and Medical Microbiology 48: 381–389.
Liao, CW, Cheng, IC, Yeh, KS, Lin, FY and Weng, CN (2001). Release characteristics of microspheres prepared by co-spray drying Actinobacillus pleuropneumoniae antigens and aqueous ethyl-cellulose dispersion. Journal of Microencapsulation 18: 285–297.
Liao, CW, Chiou, HY, Yeh, KS, Chen, JR and Weng, CN (2003). Oral immunization using formalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped in microspheres with aqueous dispersion polymers prepared using a co-spray drying process. Preventive Veterinary Medicine 61: 1–15.
Lin, L, Bei, W, Sha, Y, Liu, J, Guo, Y, Liu, W, Tu, S, He, Q and Chen, H (2007). Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1. FEMS Microbiology Letters 274: 55–62.
Liu, XS, Abdul-Jabbar, I, Qi, YM, Frazer, IH and Zhou, J (1998). Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 252: 39–45.
Lubitz, W (2001). Bacterial ghosts as carrier and targeting systems. Expert Opinion on Biological Therapy 1: 765–771.
Lubitz, W, Witte, A, Eko, FO, Kamal, M, Jechlinger, W, Brand, E, Marchart, J, Haidinger, W, Huter, V, Felnerova, D, Stralis-Alves, N, Lechleitner, S, Melzer, H, Szostak, MP, Resch, S, Mader, H, Kuen, B, Mayr, B, Mayrhofer, P, Geretschlager, R, Haslberger, A and Hensel, A (1999). Extended recombinant bacterial ghost system. Journal of Biotechnology 73: 261–273.
Maas, A, Jacobsen, ID, Meens, J and Gerlach, GF (2006a). Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals. Infection and Immunity 74: 4124–4132.
Maas, A, Meens, J, Baltes, N, Hennig-Pauka, I and Gerlach, GF (2006b). Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection. Vaccine 24: 7226–7237.
Madsen, ME, Carnahan, KG and Thwaits, RN (1995). Evaluation of pig lungs following an experimental challenge with Actinobacillus pleuropneumoniae serotype 1 and 5 in pigs inoculated with either hemolysin protein and/or outer membrane proteins. FEMS Microbiology Letters 131: 329–335.
Magnusson, U, Bosse, J, Mallard, BA, Rosendal, S and Wilkie, BN (1997). Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response. Vaccine 15: 997–1000.
Maroncle, N, Balestrino, D, Rich, C and Forestier, C (2002). Identification of Klebsiella pneumoniae genes involved in intestinal colonization and adhesion using signature-tagged mutagenesis. Infection and Immunity 70: 4729–4734.
Mattingly, JA and Waksman, BH (1980). Immunologic suppression after oral administration of antigen. II. Antigen-specific helper and suppressor factors produced by spleen cells of rats fed sheep erythrocytes. Journal of Immunology 125: 1044–1047.
Mccluskie, MJ and Davis, HL (1999). CpG DNA as mucosal adjuvant. Vaccine 18: 231–237.
Mccluskie, MJ, Weeratna, RD, Payette, PJ and Davis, HL (2002). Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunology and Medical Microbiology 32: 179–185.
Mcghee, JR, Mestecky, J, Dertzbaugh, MT, Eldridge, JH, Hirasawa, M and Kiyono, H (1992). The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10: 75–88.
Meeusen, EN, Walker, J, Peters, A, Pastoret, PP and Jungersen, G (2007). Current status of veterinary vaccines. Clinical Microbiology Reviews 20: 489–510.
Mei, JM, Nourbakhsh, F, Ford, CW and Holden, DW (1997). Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Molecular Microbiology 26: 399–407.
Mikael, LG, Pawelek, PD, Labrie, J, Sirois, M, Coulton, JW and Jacques, M (2002). Molecular cloning and characterization of the ferric hydroxamate uptake (fhu) operon in Actinobacillus pleuropneumoniae. Microbiology (Reading, England) 148: 2869–2882.
Mikael, LG, Srikumar, R, Coulton, JW and Jacques, M (2003). fhuA of Actinobacillus pleuropneumoniae encodes a ferrichrome receptor but is not regulated by iron. Infection and Immunity 71: 2911–2915.
Mistry, D and Stockley, RA (2006). IgA1 protease. The International Journal of Biochemistry and Cell Biology 38: 1244–1248.
Moller, K, Andersen, LV, Christensen, G and Kilian, M (1993). Optimalization of the detection of NAD dependent Pasteurellaceae from the respiratory tract of slaughterhouse pigs. Veterinary Microbiology 36: 261–271.
Mora, JR, Bono, MR, Manjunath, N, Weninger, W, Cavanagh, LL, Rosemblatt, M and Von Andrian, UH (2003a). Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424: 88–93.
Mora, M, Veggi, D, Santini, L, Pizza, M and Rappuoli, R (2003b). Reverse vaccinology. Drug Discovery Today 8: 459–464.
Mosier, D, Iandolo, J, Rogers, D, Uhlich, G and Crupper, S (1998). Characterization of a 54-kDa heat-shock-inducible protein of Pasteurella haemolytica. Veterinary Microbiology 60: 67–73.
Neutra, MR and Kozlowski, PA (2006). Mucosal vaccines: the promise and the challenge. Nature Reviews 6: 148–158.
Nielsen, R (1984). Haemophilus pleuropneumoniae serotypes – cross protection experiments. Nordisk Veterinaermedicin 36: 221–234.
Ogra, PL, Faden, H and Welliver, RC (2001). Vaccination strategies for mucosal immune responses. Clinical Microbiology Reviews 14: 430–445.
Pabst, R and Binns, RM (1994). The immune system of the respiratory tract in pigs. Veterinary Immunology and Immunopathology 43: 151–156.
Paradis, SE, Dubreuil, D, Rioux, S, Gottschalk, M and Jacques, M (1994). High-molecular-mass lipopolysaccharides are involved in Actinobacillus pleuropneumoniae adherence to porcine respiratory tract cells. Infection and Immunity 62: 3311–3319.
Paradis, SE, Dubreuil, JD, Gottschalk, M, Archambault, M and Jacques, M (1999). Inhibition of adherence of Actinobacillus pleuropneumoniae to porcine respiratory tract cells by monoclonal antibodies directed against LPS and partial characterization of the LPS receptors. Current Microbiology 39: 313–320.
Perry, MB, Altman, E, Brisson, J-R, Beynon, LM and Richards, JC (1990). Structural characteristics of the antigenic capsular polysaccharides and lipopolysaccharides involved in the serological classification of Actinobacillus pleuropneumoniae strains. Serodiagnosis and Immunotherapy of Infectious Diseases 4: 299–308.
Pilette, C, Ouadrhiri, Y, Godding, V, Vaerman, JP and Sibille, Y (2001). Lung mucosal immunity: immunoglobulin-A revisited. European Respiratory Journal 18: 571–588.
Pizza, M, Scarlato, V, Masignani, V, Giuliani, MM, Arico, B, Comanducci, M, Jennings, GT, Baldi, L, Bartolini, E, Capecchi, B, Galeotti, CL, Luzzi, E, Manetti, R, Marchetti, E, Mora, M, Nuti, S, Ratti, G, Santini, L, Savino, S, Scarselli, M, Storni, E, Zuo, P, Broeker, M, Hundt, E, Knapp, B, Blair, E, Mason, T, Tettelin, H, Hood, DW, Jeffries, AC, Saunders, NJ, Granoff, DM, Venter, JC, Moxon, ER, Grandi, G and Rappuoli, R (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816–1820.
Prideaux, CT, Pierce, L, Krywult, J and Hodgson, AL (1998). Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current Microbiology 37: 324–332.
Prideaux, CT, Lenghaus, C, Krywult, J and Hodgson, AL (1999). Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infection and Immunity 67: 1962–1966.
Ramjeet, M, Deslandes, V, St Michael, F, Cox, AD, Kobisch, M, Gottschalk, M and Jacques, M (2005). Truncation of the lipopolysaccharide outer core affects susceptibility to antimicrobial peptides and virulence of Actinobacillus pleuropneumoniae serotype 1. The Journal of Biological Chemistry 280: 39104–39114.
Rankin, R, Pontarollo, R, Ioannou, X, Krieg, AM, Hecker, R, Babiuk, LA and Van Drunen, Littel-Van Den Hurk S (2001). CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense and Nucleic Acid Drug Development 11: 333–340.
Rapp, VJ, Munson, RS Jr and Ross, RF (1986). Outer membrane protein profiles of Haemophilus pleuropneumoniae. Infection and Immunity 52: 414–420.
Rappuoli, R, Pizza, M, Douce, G and Dougan, G (1999). Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunology Today 20: 493–500.
Riedmann, EM, Kyd, JM, Cripps, AW and Lubitz, W (2007). Bacterial ghosts as adjuvant particles. Expert Review of Vaccines 6: 241–253.
Riesbeck, K and Nordstrom, T (2006). Structure and immunological action of the human pathogen Moraxella catarrhalis IgD-binding protein. Critical Reviews in Immunology 26: 353–376.
Rioux, S, Dubreuil, D, Begin, C, Laferriere, C, Martin, D and Jacques, M (1997) Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Comparative Immunology, Microbiology and Infectious Diseases 20: 63–74.
Rioux, S, Girard, C, Dubreuil, JD and Jacques, M (1998). Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs. Research in Veterinary Science 65: 165–167.
Rosendal, S, Miniats, OP and Sinclair, P (1986). Protective efficacy of capsule extracts of Haemophilus pleuropneumoniae in pigs and mice. Veterinary Microbiology 12: 229–240.
Rossi-Campos, A, Anderson, C, Gerlach, GF, Klashinsky, S, Potter, AA and Willson, PJ (1992). Immunization of pigs against Actinobacillus pleuropneumoniae with two recombinant protein preparations. Vaccine 10: 512–518.
Ryan, EJ, Daly, LM and Mills, KH (2001). Immunomodulators and delivery systems for vaccination by mucosal routes. Trends in Biotechnology 19: 293–304.
San, Gil F, Turner, B, Walker, MJ, Djordjevic, SP and Chin, JC (1999). Contribution of adjuvant to adaptive immune responses in mice against Actinobacillus pleuropneumoniae. Microbiology (Reading, England) 145: 2595–2603.
Saze, K, Kinoshita, C, Shiba, F, Haga, Y, Sudo, T and Hashimoto, K (1994). Effect of passive immunization with serotype-specific monoclonal antibodies on Actinobacillus pleuropneumoniae infection of mice. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 56: 97–102.
Schaller, A, Kuhn, R, Kuhnert, P, Nicolet, J, Anderson, TJ, Macinnes, JI, Segers, RP and Frey, J (1999). Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae. Microbiology (Reading, England) 145: 2105–2116.
Seah, JN and Kwang, J (2004). Localization of linear cytotoxic and pro-apoptotic epitopes in RTX toxin ApxIII of Actinobacillus pleuropneumoniae. Vaccine 22: 1494–1497.
Seah, JN, Frey, J and Kwang, J (2002). The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infection and Immunity 70: 6464–6467.
Serruto, D and Rappuoli, R (2006). Post-genomic vaccine development. FEBS Letters 580: 2985–2992.
Shakarji, L, Mikael, LG, Srikumar, R, Kobisch, M, Coulton, JW and Jacques, M (2006). Fhua and HgbA, outer membrane proteins of Actinobacillus pleuropneumoniae: their role as virulence determinants. Canadian Journal of Microbiology 52: 391–396.
Shea, RJ and Mulks, MH (2002). ohr, Encoding an organic hydroperoxide reductase, is an in vivo-induced gene in Actinobacillus pleuropneumoniae. Infection and Immunity 70: 794–802.
Sheehan, BJ, Langford, PR, Rycroft, AN and Kroll, JS (2000). [Cu,Zn]-Superoxide dismutase mutants of the swine pathogen Actinobacillus pleuropneumoniae are unattenuated in infections of the natural host. Infection and Immunity 68: 4778–4781.
Sheehan, BJ, Bosse, JT, Beddek, AJ, Rycroft, AN, Kroll, JS and Langford, PR (2003). Identification of Actinobacillus pleuropneumoniae genes important for survival during infection in its natural host. Infection and Immunity 71: 3960–3970.
Shin, NR, Choi, IS, Kim, JM, Hur, W and Yoo, HS (2002). Effective methods for the production of immunoglobulin Y using immunogens of Bordetella bronchiseptica, Pasteurella multocida and Actinobacillus pleuropneumoniae. Journal of Veterinary Science (Suwon-si, Korea) 3: 47–57.
Shin, SJ, Bae, JL, Cho, YW, Lee, DY, Kim, DH, Yang, MS, Jang, YS and Yoo, HS (2005). Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunology and Medical Microbiology 43: 155–164.
Sidibe, M, Messier, S, Lariviere, S, Gottschalk, M and Mittal, KR (1993). Detection of Actinobacillus pleuropneumoniae in the porcine upper respiratory tract as a complement to serological tests. Canadian Journal of Veterinary Research=Revue Canadienne de Recherche Veterinaire 57: 204–208.
Slauch, JM, Mahan, MJ and Mekalanos, JJ (1994). In vivo expression technology for selection of bacterial genes specifically induced in host tissues. Methods Enzymology 235: 481–492.
Sosroseno, W (1995). A review of the mechanisms of oral tolerance and immunotherapy. Journal of the Royal Society of Medicine 88: 14–17.
Srikumar, R, Mikael, LG, Pawelek, PD, Khamessan, A, Gibbs, BF, Jacques, M and Coulton, JW (2004). Molecular cloning of haemoglobin-binding protein HgbA in the outer membrane of Actinobacillus pleuropneumoniae. Microbiology (Reading, England) 150: 1723–1734.
St Geme, III JW, Cutter, D and Barenkamp, SJ (1996). Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. Journal of Bacteriology 178: 6281–6287.
Sun, YH, Bakshi, S, Chalmers, R and Tang, CM (2000). Functional genomics of Neisseria meningitidis pathogenesis. Nature Medicine 6: 1269–1273.
Szostak, MP, Hensel, A, Eko, FO, Klein, R, Auer, T, Mader, H, Haslberger, A, Bunka, S, Wanner, G and Lubitz, W (1996). Bacterial ghosts: non-living candidate vaccines. Journal of Biotechnology 44: 161–170.
Takahashi, I, Marinaro, M, Kiyono, H, Jackson, RJ, Nakagawa, I, Fujihashi, K, Hamada, S, Clements, JD, Bost, KL and Mcghee, JR (1996). Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. The Journal of Infectious Diseases 173: 627–635.
Taylor, DJ (1999). In: Straw, BE, D'allaire, S, Megeling, WL and Taylor, DJ (eds) Diseases of Swine. Ames, IA: Iowa State University Press. 8th edn, pp. 343–354.
Thacker, BJ and Mulks, MH (1988). Evaluation of commercial Haemophilus pleuropneumoniae vaccines. Proceedings of International Pig Veterinary Society Congress 10: 87.
Thomas, LD, Dunkley, ML, Moore, R, Reynolds, S, Bastin, DA, Kyd, JM and Cripps, AW (2000). Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine 19: 348–357.
Tonpitak, W, Thiede, S, Oswald, W, Baltes, N and Gerlach, GF (2000). Actinobacillus pleuropneumoniae iron transport: a set of exbBD genes is transcriptionally linked to the tbpB gene and required for utilization of transferrin-bound iron. Infection and Immunity 68: 1164–1170.
Tonpitak, W, Baltes, N, Hennig-Pauka, I and Gerlach, GF (2002). Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infection and Immunity 70: 7120–7125.
Tumamao, JQ, Bowles, RE, Van Den Bosch, H, Klaasen, HL, Fenwick, BW, Storie, GJ and Blackall, PJ (2004). Comparison of the efficacy of a subunit and a live streptomycin-dependent porcine pleuropneumonia vaccine. Australian Veterinary Journal 82: 370–374.
Van Den Bosch, H and Frey, J (2003). Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs. Vaccine 21: 3601–3607.
Van Den Bosch, JF, Jongenelen, IMCA, Pubben, NB, Van Vugt, FGA and Segers, RPaM (1992). Protection induced by a trivalent Actinobacillus pleuropneumoniae subunit vaccine. Proceedings of 12th International Pig Veterinary Society Congress, p. 194.
Van Overbeke, I, Chiers, K, Ducatelle, R and Haesebrouck, F (2001). Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. Journal of Veterinary Medicine 48: 15–20.
Van Overbeke, I, Chiers, K, Donne, E, Ducatelle, R and Haesebrouck, F (2003). Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 10 of pigs vaccinated with bacterins consisting of A. pleuropneumoniae serotype 10 grown under NAD-rich and NAD-restricted conditions. Journal of Veterinary Medicine 50: 289–293.
Wagner, TK and Mulks, MH (2006). A subset of Actinobacillus pleuropneumoniae in vivo induced promoters respond to branched-chain amino acid limitation. FEMS Immunology and Medical Microbiology 48: 192–204.
Wagner, TK and Mulks, MH (2007). Identification of the Actinobacillus pleuropneumoniae leucine-responsive regulatory protein and its involvement in the regulation of in vivo-induced genes. Infection and Immunity 75: 91–103.
Wang, J, Mushegian, A, Lory, S and Jin, S (1996). Large-scale isolation of candidate virulence genes of Pseudomonas aeruginosa by in vivo selection. Proceedings of National Academy of Sciences, USA 93: 10434–10439.
Williams, NA, Hirst, TR and Nashar, TO (1999). Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunology Today 20: 95–101.
Willson, PJ, Rossi-Campos, A and Potter, AA (1995). Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Canadian Journal of Veterinary Research=Revue Canadienne de Recherche Veterinaire 59: 299–305.
Willson, PJ, Gerlach, GF, Klashinsky, S and Potter, AA (2001). Cloning and characterization of the gene coding for NADPH-sulfite reductase hemoprotein from Actinobacillus pleuropneumoniae and use of the protein product as a vaccine. Canadian Journal of Veterinary Research=Revue Canadienne de Recherche Veterinaire 65: 206–212.
Witte, A, Wanner, G, Blasi, U, Halfmann, G, Szostak, M and Lubitz, W (1990). Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. Journal of Bacteriology 172: 4109–4114.
Witte, A, Wanner, G, Sulzner, M and Lubitz, W (1992). Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Archives of Microbiology 157: 381–388.
Woof, JM and Kerr, MA (2006). The function of immunoglobulin A in immunity. The Journal of Pathology 208: 270–282.
Xu, F, Chen, X, Shi, A, Yang, B, Wang, J, Li, Y, Guo, X, Blackall, PJ and Yang, H (2006). Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae. Veterinary Microbiology 118: 230–239.